Maya S Safarova1, Hongfang Liu2, Iftikhar J Kullo3. 1. Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA. 2. Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. 3. Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA. Electronic address: Kullo.Iftikhar@mayo.edu.
Abstract
BACKGROUND: Little is known about prevalence, awareness, and control of familial hypercholesterolemia (FH) in the United States. OBJECTIVE: To address these knowledge gaps, we developed an ePhenotyping algorithm for rapid identification of FH in electronic health records (EHRs) and deployed it in the Screening Employees And Residents in the Community for Hypercholesterolemia (SEARCH) study. METHODS: We queried a database of 131,000 individuals seen between 1993 and 2014 in primary care practice to identify 5992 (mean age 52 ± 13 years, 42% men) patients with low-density lipoprotein cholesterol (LDL-C) ≥190 mg/dL, triglycerides <400 mg/dL and without secondary causes of hyperlipidemia. RESULTS: Our EHR-based algorithm ascertained the Dutch Lipid Clinic Network criteria for FH using structured data sets and natural language processing for family history and presence of FH stigmata on physical examination. Blinded expert review revealed positive and negative predictive values for the SEARCH algorithm at 94% and 97%, respectively. The algorithm identified 32 definite and 391 probable cases with an overall FH prevalence of 0.32% (1:310). Only 55% of the FH cases had a diagnosis code relevant to FH. Mean LDL-C at the time of FH ascertainment was 237 mg/dL; at follow-up, 70% (298 of 423) of patients were on lipid-lowering treatment with 80% achieving an LDL-C ≤100 mg/dL. Of treated FH patients with premature CHD, only 22% (48 of 221) achieved an LDL-C ≤70 mg/dL. CONCLUSIONS: In a primary care setting, we found the prevalence of FH to be 1:310 with low awareness and control. Further studies are needed to assess whether automated detection of FH in EHR improves patient outcomes.
BACKGROUND: Little is known about prevalence, awareness, and control of familial hypercholesterolemia (FH) in the United States. OBJECTIVE: To address these knowledge gaps, we developed an ePhenotyping algorithm for rapid identification of FH in electronic health records (EHRs) and deployed it in the Screening Employees And Residents in the Community for Hypercholesterolemia (SEARCH) study. METHODS: We queried a database of 131,000 individuals seen between 1993 and 2014 in primary care practice to identify 5992 (mean age 52 ± 13 years, 42% men) patients with low-density lipoprotein cholesterol (LDL-C) ≥190 mg/dL, triglycerides <400 mg/dL and without secondary causes of hyperlipidemia. RESULTS: Our EHR-based algorithm ascertained the Dutch Lipid Clinic Network criteria for FH using structured data sets and natural language processing for family history and presence of FH stigmata on physical examination. Blinded expert review revealed positive and negative predictive values for the SEARCH algorithm at 94% and 97%, respectively. The algorithm identified 32 definite and 391 probable cases with an overall FH prevalence of 0.32% (1:310). Only 55% of the FH cases had a diagnosis code relevant to FH. Mean LDL-C at the time of FH ascertainment was 237 mg/dL; at follow-up, 70% (298 of 423) of patients were on lipid-lowering treatment with 80% achieving an LDL-C ≤100 mg/dL. Of treated FH patients with premature CHD, only 22% (48 of 221) achieved an LDL-C ≤70 mg/dL. CONCLUSIONS: In a primary care setting, we found the prevalence of FH to be 1:310 with low awareness and control. Further studies are needed to assess whether automated detection of FH in EHR improves patient outcomes.
Authors: Omri Gottesman; Helena Kuivaniemi; Gerard Tromp; W Andrew Faucett; Rongling Li; Teri A Manolio; Saskia C Sanderson; Joseph Kannry; Randi Zinberg; Melissa A Basford; Murray Brilliant; David J Carey; Rex L Chisholm; Christopher G Chute; John J Connolly; David Crosslin; Joshua C Denny; Carlos J Gallego; Jonathan L Haines; Hakon Hakonarson; John Harley; Gail P Jarvik; Isaac Kohane; Iftikhar J Kullo; Eric B Larson; Catherine McCarty; Marylyn D Ritchie; Dan M Roden; Maureen E Smith; Erwin P Böttinger; Marc S Williams Journal: Genet Med Date: 2013-06-06 Impact factor: 8.822
Authors: Raul D Santos; P Barton Duell; Cara East; John R Guyton; Patrick M Moriarty; Wai Chin; Robert S Mittleman Journal: Eur Heart J Date: 2013-12-23 Impact factor: 29.983
Authors: Chung-Il Wi; Sunghwan Sohn; Mary C Rolfes; Alicia Seabright; Euijung Ryu; Gretchen Voge; Kay A Bachman; Miguel A Park; Hirohito Kita; Ivana T Croghan; Hongfang Liu; Young J Juhn Journal: Am J Respir Crit Care Med Date: 2017-08-15 Impact factor: 21.405
Authors: Candace L Jackson; James Z Keeton; Stephen J Eason; Zahid A Ahmad; Colby R Ayers; M Odette Gore; Darren K McGuire; Merlyn H Sayers; Amit Khera Journal: JAMA Cardiol Date: 2019-07-01 Impact factor: 14.676
Authors: Gerald F Watts; Samuel S Gidding; Pedro Mata; Jing Pang; David R Sullivan; Shizuya Yamashita; Frederick J Raal; Raul D Santos; Kausik K Ray Journal: Nat Rev Cardiol Date: 2020-01-23 Impact factor: 32.419
Authors: Laney K Jones; Nicole Walters; Andrew Brangan; Catherine D Ahmed; Michael Gatusky; Gemme Campbell-Salome; Ilene G Ladd; Amanda Sheldon; Samuel S Gidding; Mary P McGowan; Alanna K Rahm; Amy C Sturm Journal: J Pers Med Date: 2021-06-21
Authors: Muin J Khoury; M Scott Bowen; Mindy Clyne; W David Dotson; Marta L Gwinn; Ridgely Fisk Green; Katherine Kolor; Juan L Rodriguez; Anja Wulf; Wei Yu Journal: Genet Med Date: 2017-12-14 Impact factor: 8.822